Prediction and Evaluation by ETCOc of Neonatal Hyperbilirubinemia Cohort
Trial Parameters
Brief Summary
The hemolytic disease of newborns (HDN) is one of the most significant risk factors for hyperbilirubinemia. Studies have shown that end-tidal carbon monoxide-corrected (ETCOc) correlated with the rate of bilirubin production in the body and thus can be a good surrogate to quantify hemolysis and identifying the high-risk infants. However, there is insufficient clinical evidence regarding the early prediction of hemolytic hyperbilirubinemia using ETCOc. This study hypothesizes that early postnatal ETCOc levels are significantly associated with the risk of hemolytic hyperbilirubinemia requiring treatments within 14 days after birth, and early postnatal ETCOc can be a good indicator for early prediction of hemolysis. In addition, the investigators aim to investigate the relationship between the characteristics of treatments for hyperbilirubinemia and ETCOc.
Eligibility Criteria
Inclusion Criteria: * Infants who are born at gestational age ≥35 weeks and with a birth weight ≥2000 grams within 72 hours after birth * Infants who are born at study centers * Infants with the informed consent obtained from the parents or legal guardians Exclusion Criteria: * Immediate requirement of respiratory support after birth (e.g., mechanical ventilation, nasal high-flow cannula oxygen therapy) * Mothers who have active tobacco smoking or continuous environmental tobacco exposure during pregnancy * Major congenital anomalies (e.g., cardiac or lung abnormalities, lethal chromosomal defects) * The presence of injury of nasal mucosa, choanal atresia or Pierre Robin Sequence